<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04576910</url>
  </required_header>
  <id_info>
    <org_study_id>ZJCDC202002701</org_study_id>
    <nct_id>NCT04576910</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China</brief_title>
  <official_title>Immunogenicity and Safety of the Booster Dose of Polio Vaccine Immunization Using Sabin IPV or bOPV at Children Aged 4 Years With Different Three Sequential Schedules History by Sabin IPV or bOPV in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Provincial Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China National Biotec Group Company ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Provincial Center for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the immunogenicity and safety of Sabin IPV or bOPV, given as a&#xD;
      booster vaccination in children aged 4 years who were previously immunised with different&#xD;
      sequential immunization history by Sabin IPV and bOPV, and to observe the antibody&#xD;
      persistence three years after different primary sequential immunization with Sabin IPV or&#xD;
      bOPV at age 2, 3 and 4 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a continuous study of preliminary trial (Immunogenicity of three sequential schedules&#xD;
      with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang,&#xD;
      China: NCT03147560) . The investigators will follow up previous participants at age 4 years&#xD;
      old with different primary sequential immunization schedules at age 2, 3 and 4 months:&#xD;
      sIPV-bOPV-bOPV , sIPV-sIPV-bOPV , or sIPV-sIPV-sIPV, and give the 4th doses of polio vaccine&#xD;
      with Sabin IPV or bOPV. A pre-vaccination blood sample is taken for polio antibody&#xD;
      determinations. Sabin IPV will be administrated for participants in the previous Group 1&#xD;
      (sIPV-bOPV-bOPV), and Sabin IPV or bOPV will be given for participants in the previous Group&#xD;
      2 (sIPV-sIPV-bOPV) and Group 3 (sIPV-sIPV-sIPV) after they were randomly divided into two&#xD;
      subgroups. At least two active surveillance visits, during which staff visited the&#xD;
      participants s at home (on days 3 and 30) will required after vaccination to collect adverse&#xD;
      reaction data. Parents or legal guardians were instructed to contact investigators if they&#xD;
      observed any possible vaccine-related adverse events or important medical events (such as&#xD;
      serious illness, physical disability, or death). The second blood sample will be collected&#xD;
      28-60 days after the booster vaccination. The investigators will asess the immunogenicity by&#xD;
      seroconversion rate and seropositivity after the booster vaccination, and evaluate the&#xD;
      antibody persistence using seropositive rate and GMT in participants before the booster&#xD;
      vaccination. Safety will assessed with the occurrence of adverse events reported across the&#xD;
      study groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rates of the booster vaccination</measure>
    <time_frame>before and 28-60 days after the booster dose (4 years old) of polio vaccine</time_frame>
    <description>Defined as any positive antibody (titre ≥ 8) response in children who were seronegative prior to the vaccination, or at least a fourfold increase in type-specific antibody levels for children who had pre-existing positive antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistence (tite rates) of antibodies against poliovirus 3 years after the primary 3 dose polio vaccine immunization</measure>
    <time_frame>3 years after the primary three doses of polio immunization(before the booster vaccination )</time_frame>
    <description>The percentage of participants with positive antibody(titre ≥ 8) against all three serotypes of poliovirus 3 years after the primary immunization with different sequential immunization schedules using sIPV or bOPV</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection rates after the booster vaccination</measure>
    <time_frame>28-60 days after the booster dose (4 years old) of polio vaccine</time_frame>
    <description>The percentage of participants with positive antibody(titre ≥ 8) against all three serotypes of poliovirus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of the booster dose of polio vaccine immunization</measure>
    <time_frame>30 days after the booster vaccination</time_frame>
    <description>the occurrence of adverse events for the booster dose of Polio vaccine administered at age 4 using Sabin IPV or bOPV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titers pesistence against poliovirus</measure>
    <time_frame>3 years after the primary three doses of polio immunization(before the booster vaccination )</time_frame>
    <description>Geometric Mean Titres (GMTs) or Median antibody titers for three poliovirus types</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titers against poliovirus after the booster immunization</measure>
    <time_frame>28-60 days after the booster dose of polio vaccine given</time_frame>
    <description>Geometric Mean Titres (GMTs) or Median antibody titers for three poliovirus types after the booster dose of Polio vaccine administered at age 4 using Sabin IPV or bOPV</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Polio</condition>
  <condition>Vaccine Reaction</condition>
  <arm_group>
    <arm_group_label>Group A(&quot;Sabin IPV+ bOPV+ bOPV&quot;+Sabin IPV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 1 of preliminary study (NCT03147560).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B(&quot;Sabin IPV+ Sabin IPV+ bOPV&quot;+bOPV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give the 4th doses of polio vaccine with bOPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C(&quot;Sabin IPV+ Sabin IPV+ bOPV&quot;+Sabin IPV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D(&quot;Sabin IPV+ Sabin IPV+ Sabin IPV&quot;+bOPV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give the 4th doses of polio vaccine with bOPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E(&quot;Sabin IPV+ Sabin IPV+ Sabin IPV&quot;+Sabin IPV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>vaccinated with Sabin IPV</intervention_name>
    <description>the 4th dose of polio vaccination</description>
    <arm_group_label>Group A(&quot;Sabin IPV+ bOPV+ bOPV&quot;+Sabin IPV)</arm_group_label>
    <arm_group_label>Group C(&quot;Sabin IPV+ Sabin IPV+ bOPV&quot;+Sabin IPV)</arm_group_label>
    <arm_group_label>Group E(&quot;Sabin IPV+ Sabin IPV+ Sabin IPV&quot;+Sabin IPV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>vaccinated with bOPV</intervention_name>
    <description>the 4th dose of polio vaccination</description>
    <arm_group_label>Group B(&quot;Sabin IPV+ Sabin IPV+ bOPV&quot;+bOPV)</arm_group_label>
    <arm_group_label>Group D(&quot;Sabin IPV+ Sabin IPV+ Sabin IPV&quot;+bOPV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants aged ≥48 months to ≤ 51 months from preliminary study (NCT03147560) with&#xD;
             sequential immunization history by Sabin IPV and bOPV.&#xD;
&#xD;
          -  Parent/legal acceptable representative is willing and able to understand the protocol&#xD;
             requirements and provide informed consent.&#xD;
&#xD;
          -  ≥ 14 days interval between the last vaccination.&#xD;
&#xD;
          -  Body temperature ≤ 37.2℃.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known acute illness, severe chronic disease, acute exacerbation of chronic disease and&#xD;
             fever.&#xD;
&#xD;
          -  Known allergy to any constituent of the vaccine.&#xD;
&#xD;
          -  Had 4 doses vaccination record of polio vaccine.&#xD;
&#xD;
          -  Known impairment of immunologic function, or receipt of immunosuppressive therapy or&#xD;
             immunoglobulin .&#xD;
&#xD;
          -  Received non-specific immunoglobulin within 1 month.&#xD;
&#xD;
          -  An acute illness with fever (temperature ≥ 37.3℃) or any infectious diseases.&#xD;
&#xD;
          -  Patients with a well-diagnosed history of thrombocytopenia or other coagulation&#xD;
             disorders that may cause contraindications for injection.&#xD;
&#xD;
          -  Any condition which, in the opinion of the investigator, would pose a health risk to&#xD;
             the subject or interfere with the vaccine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>48 Months</minimum_age>
    <maximum_age>51 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chunan center for disease control and prevention</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longyou Center for Disease Control and Prevention</name>
      <address>
        <city>Quzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunogenicity</keyword>
  <keyword>Antibody persistence</keyword>
  <keyword>Safety</keyword>
  <keyword>Sabin IPV</keyword>
  <keyword>bOPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

